cicc-9-israeli-startups-covid-relatedpdf
cicc-9-israeli-startups-covid-relatedpdf
Page 1 of 100
Jason Ciment shared this file. Want to do more with it?
  2. Resmetrix develops unqiue wearable respiratory monitoring system that can detect and alart on early signs of Covid-19 patients deterioration at home &hospitalCOMPANY OVERVIEWUnique platform that provides professional predictive analytics of respiratory condition at home, using our unique proprietary sensor and the power of AL & MLWon 2 IIA grants for fighiting Covid-19 and for COPD monitoring (>$900K)Selectedfor prestiguious JVP & AstraZeneca digital health program (April 2020)US patent no: 10194835MANAGEMENT TEAMTeam of engineerscombines business experienceand medical experts in healthcareDr. Carmit LevyCo-Founder &CEOcarmit@resmetrix-medical.comDr Zvi ReznicCo-Founder &Technology advisorDr Ari DeRoweCo-Founder & Medical advisorProf David GozalKOL -Clinical advisory boardINVESTORSMindUP incubatorBUSINESS SUMMARYResmetrixis a digital health startup that developed a platform that provide professional analytics of respiratory condition of respiratory disease patients (Covid-19, COPD, Asthma).OPPORTUNITYOver 3 millionpeople are infected with Covid-19virus and require tight monitoring of their clinical condition from a distance, especially their lung function, both at home or isolated area &at hospital. The main symptom of all deteriorating patients is shortness of breath &breathing difficulties. None of the current methodsdetect this symptom. Moreover, many mild patients are deteriorating fast, reaching ER with severe pneumonia and require mechanical ventilation and are at high risk of death(80%).Resmetrix unique telemonitoring system can early detect lung deterioration of Covid-19 patients, sendalarm to the patient andcare giver that willallow early treatment that can save lives. SOLUTIONResmetrix unique wearable sensor (based on novel proprietary sensor built into a chest strap or a patch over the chest), wirelessly connected to a smartphone app, that monitors at-risk patients in real-time, 24/7, anywhere, in any setting. Resmetrix system is the only system that detects small changes in a patient’s breathing pattern, tidal volume and other vital signs (Heart Rate, Temperature) and will provide immediate, early warning signs of deterioration in lung function (based on each patient respiratory pattern)anywhere and anytime.AL & ML analytic tools will be used to provide for the first-timeprofessional analysis of patient'srespiratory condition in various respiratory diseases. Technology is based on stretchable radio-frequency transmission line chest sensor, that allows accurate respiratory pattern measurement in real time.Clinical validation on 32 patients:High correlation of Resmetrix signals to Spirometer tidal volume Feasibility for early detection of Asthma attackbefore patients symptomsTHE MARKETHospital & home monitoring (disease management) of Covid-19 patients and chronic lung disease patient'sCOPD & Asthma.Customers are hospitals and at later stage payers.GO TO MARKETDirect sale to hospitals and medical centers with distributors. For home monitoring Resmetrix will use telemonitoring centers. REVENUE MODELFor Hospitals & Medical centers Resmetrix system -$180 per patient (one-timepayment). For disease management (COPD) -$150 Sensor per patient and$30 monthly service fee. Future application will include disposable patch ($50 per 5 days)NOTESwww.resmetrix-medical.com | Israel: +972 (54) 3057332| info@resmetrix-medical.com
  3. EchoCare improves the remote senior care by an advanced Non-Wearable & Non-Invasive monitoring system that detectsemergencies at home as well as supporting thepreventive careapproach.COMPANY OVERVIEWAn award-winning solution:Japanese METI:Best elderly care technology company at the 'Quality Digital Health'business session(2ndWASS, Tokyo,Oct 2019)Centrica ‘Active aging challenge’-2ndPrize out of 125 W.W.companies(London 2018)Aging2.0 OPTIMIZE: Top 10(out of 400) technology startups for Elderly-Care(S.F.Nov. 2016)Aging2.0Global Startup Search: 1stplace (Boston, May 2016)PATENTSSystem and technology are protected by 6 US patents no:US9520051, US 9576468, US 9568594, US 9568595, US 10037671, US10621847MANAGEMENT & TEAMEntrepreneurswith 30 yearsof experience in management, entrepreneurship &technologyRafi ZackCo-founder,CEO& VP R&Drafiz@echocare-tech.comDr. Yossi KofmanCo-founder and Executive directorYossi@echocare-tech.comAn expert multidisciplinary teamwith more than 125 accumulated yearsof RADAR, HW, SW, Signal Processing, AI&MLtechnologies2 BizDev5 R&D Engineers (4-M.Sc, 1-B.Sc)INVESTORSIncubit Technologies Venture (Israel)SMK Corporation (Japan)Centrica Innovation (UK)LifeView residential care (Australia)Tigbur Group (Israel)BUSINESS SUMMARYEchoCare developsthe Elderly Care Home Observer(ECHO),an elderly care home monitoring system,that detectsvarious emergencies (e.g. falls, drowning in a bathtuborrespiration distress) and a potential health deterioration (e.g. high risk for fallsorMild Cognitive Impairment)by monitoring the person Activity of Daily Living (ADL).In the current COVID19period,the ECHO system becomesvery essentialas it can continuouslymonitorthe respiration profileofquarantined seniorsat their homesand COVID19 patients in hospital.The EchoCare’ssolution consists of the installed ECHO device and the cloud service that enables the transferof the alerts and other vital data to the remote caregiverusing a web based nursing call system (dashboard).Our affordable system improves the quality of livesof the senior community andenhances their at-home safetyat a reduced cost of care to caregivers.OPPORTUNITYThe need for the ECHO system is driven from several major and long-term trends:The number of elderly people is growing constantlyas they live longer. In the US, there are 53M seniors and it will grow toover 80M in 2050.Therefore the risk for a distress (e.g. fall) at their home is increased as well.The number of potential caregivers per family member is decreasingIn pandemic cases,such as COVID19,the senior people should be quarantined with no visitors.As a result of the above, the costs for the health systems are getting higher and, actually, start to get out of control(E.g. The annual burden of elderly falls alone on the US health system is expected to reach 68 billion USD in 2020).This implies that a paradigm shift is required, in which the focus will shift to prevention, alert and quick response to emergency situations. The ECHO system provides exactly these functionalities, which combinesboth PERS (Personal Emergency Response System) and ADL (Activity of Daily Living) along with machine learning and big data analytics.The EchoCare’s addressable market is >$15B.SOLUTIONThe ECHO system is based on a unique radar. It transmits a very low power Ultra-Wideband radio signal into the home environment and receives back the reflected signal. The RADAR can distinguish between the human body and the home environment as well as pets.It continuously tracks four essential body indicators: the person location, posture, motion and respiration followed byAI engine that determineswhether there is any emergency or abnormal situation.The device also learns the person’s daily activities (Machine Learning) by monitoring the person’sPhysical activities, Home usage and the walking profile (Gait). The ECHOalerts in case of a significant deviation versus the last period.The device is installed at the apartmentceiling and is connected to the cloud. The ECHO cloud collects the multiple users’ un-tagged data to learn new (unknown) cases for further big data analysis.(Introduction video: https://www.youtube.com/watch?v=OeB3SRLpiAA)THE MARKETEchoCare targets two main market segments for its ECHO systemRemote senior care (Senior living facilities, Remote Home Care)Remote COVID19 patient monitoring (Hospitals/Homes)GO TO MARKETEchoCare promotes its system through regional healthcare distributors, partners(System Integrators) and directly to itsB2B customers (senior living facilities, caregiver operators, remote home careservice centersand hospitals)REVENUE MODELSelling the ECHO unitAnnual subscription for the cloud services (SW upgrade, new functionalities,dashboardand connectivity to 3rdpartyEHR).NOTESwww.echocare-tech.com| Israel: +972 (8) 6188883| Contact: Rafi Zack rafiz@echocare-tech.com|
  4. 19 HaMesila St.,Nesher,3688519,Israel |Tel: +972-4-832-1663 | info@sanolla.com|www.sanolla.comIn the current extremely challenging COVID-19 pandemic, Sanolla’s solutions can be harnessed for effective screening as well as monitoring of quarantined patients. Sanolla has started multi-center clinical trial for classifying COVID-19 patients lung sounds.Sanolla is a digital healthcare platform company, focusing onSmart Primary Care Diagnosis Solutions both for clinic and home-use self-assessment, based on AI-powered detection and analysis of previously inaccessible body infra-sounds.SANOLLA IN NUMBERS•Established in 2016•11 employees•3 product lines•3 patents granted, 5 patents pending•ISO 13485 certified•Funds raised to date: $5 millionMANAGEMENT TEAMMoshe Barel, MSc-CEOMoshe has extensive experience in business development, both in startups and global corporations.•NovaSight -VP Strategy •Lumenis -BU Director •Johnson & Johnson -BU Managermoshe@sanolla.comDr. Doron Adler, PhD-Founder &CTO Dr. Adler is a serial entrepreneur, with more than 40 years of experience in the med-tech industry. •CByond –Founder & CEO (Sold to Olympus for $2.1B)•Olympus Israel -CEO•Olympus US -CTO•Given Imaging -VP R&Ddoron@sanolla.comDavid Linhard, MBA-Co-Founder & COODavid is an experienced operational executive, scaling up manufacturing from prototype to sales of hundreds of thousands of units.•CByond -VP Operations•Olympus Israel –COOdudu@sanolla.comINVESTORSNextLeap Ventureshttps://nextleapventures.com/Private investorsInnovation Authority GrantTHE UNMET NEEDMost primary care still requires on-site visits, which are time consuming and driving costs. The COVID-19 pandemic has presented a whole new level of complexity, with every visit to the doctor’s office becoming unsafe, with risk of exposure to medical staff and other patients. Stethoscopes being used in every diagnosis lack accuracy as they depend on the subjective skills of the physician to detect and classifybody sounds, and they can transmit only the audible range of sounds, neglecting important clinical information in the infrasoundthat our body produces. Even telemedicine solutions are limitedas they require online physiciansto interpret the results, and they too cannot detect infrasound.PRODUCTSThe VoqX™is a SMARTstethoscopewith the ability to detect, record and analyze all body sounds including infrasound. It has on-device AI-powered disease classifier –doctor decision support, and it can take vital signs measurement –body temperature, oxygen, pulse and respiratory cycle.The PyXy™is a clinic at home, providing immediateself-assessment and monitoring. It is intuitiveandeasy to use, minimizingthe need for doctor visits, savingtime, costand reducingexposure risk.THE MARKETOur target audience for the VoqX are health care professionals(more than 15millionworldwide), and the target audience for the PyXy are households with young children, elderly patientsor patients suffering from severe chroniccardiopulmonary diseases.GO TO MARKETSanolla received a letter of intent from Riester–a leading global medical diagnostic devices player (part of HALMAcorporate, market cap $7B) for the purchase of 20,000units of VoqX annually. For the PyXy device Sanolla plans to employ a direct to patientstrategy through online sales, social media campaignsand through pharmacies and other points of sales.BUSINESS MODEL&ADDRESSABLE MARKET VoqX-There are around 3 million stethoscopessold annually, and with an end user price of $800, the addressable market is valued at $2.4 B.PyXy-There are around 1B households with children in the target regions,our target audience will be the top 5% =50 million households. In addition,there are 40 million patients suffering from severe chronic cardiopulmonary diseases, comprising together an addressable market of 90 million people. The pricingmodelforthe PyXy has anend user price of $99 plus $9 monthly subscription fee. With estimatedusage time of 5 years per customer, the patient lifetime value is estimated at $639. Thus, the overall addressable market value is $57B.OPPORTUNITYSanolla is playing in the global digital health market which is projected to generate $423B by 2024. With the COVID-19 pandemic effect we expect to see more funds allocated by governments and organizationsto smart digital solutions for primary care diagnosis.Key Investment Merits•LOI from Riester –20,000 units per year•Excellent clinical results•FDA registration due June 2020•Huge addressable market
  5. The CardiaCarewristband wearable provides a complete telehealth solution of monitoring and therapyfor cardiac arrhythmias. Our award-winning platform differs from all other wearables by actually delivering neuromodulation therapy.Withremote diagnostic and therapeutic capabilities,wecreate patient reassurance of physical and emotional well-being.COMPANY OVERVIEWAn award-winning platformandan expert multidisciplinary team:•ICI 2019 best startup in cardiology•IIA grantCollaboration with leading institutions•Mount Sinai•Sheba Medical CenterProtected by US patent no: 15/761,624MANAGEMENT TEAM•Amos Ziv, MSc, CEO & Founder.•Amalia Herszkowicz MBA, COO, Co-Founder •Tsahi Hollnd MSc, CTO, Co-Founder. •Ron Sacher, MBA, Premia spine•Dr. ViVek Reddy, MD, Mount Sinai Cardiology•Dr. Roy Beinart, MD, Head of EP Unit, Sheba Medical Center,Israel•Prof. dr. H.J.G.M., Crijns, MD, Cardiovascular Research Institute Maastrich, HollandINVESTORSYoram LevinsonYaron HakimiBUSINESS SUMMARYCardiaCare is a digital therapeutic company that offersthe world's first therapydeliveringand continuous monitoringwearabletechnologyaimedfor treating and preventing cardiac arrythmias, specifically atrial fibrillation(AFib).Ourtechnology utilizes noninvasive neuromodulation(nerve stimulation)thataffectsthe central nervoussystemand the cardiovascularsystemtoreducearrhythmiatriggers. Weemploya closed loop approach involving both monitoring and therapy.Our solution is global and scalable yet personalizedto specific patientneeds.With expert leadership CardiaCare has recentlysubmitteda protocolsfor human clinical trialsin Mount SinaiNYand Sheba Medical Center in IL.OPPORTUNITYWorldwide, 35 million and in the US 7 million people suffer fromatrial fibrillation (AFib). These numbers are projected to reach 70M (WW) and 11.5M (US) by 2050. Out of the 5 millionnew people that get atrial fibrillation each year, 650 thousand end up dying from complications such as stroke. Patients with AFib suffer from limiting symptoms such as palpitations, chest pain, shortness of breath, anxiety dizziness and fatigue. Unbalanced autonomic nervous system (ANS) tone, and development and progression of AFib.SOLUTIONCardiaCare'stele-health solutionoperates continuous monitoring and remote first-phasetherapythatcan detect,treat and prevent early stages of AFib .Ourwearable wristbandcombines advanced ECG and PPG sensors withAI based algorithmsfor neuromodulation therapy. The systemstemmed from clinical practice and thus far demonstrated the ability to detect and reduce arrhythmiaburdenin more than 100 patients.Our closed loop solution of monitoring, health care provider alertsand cloud-basedcommunication providesremotediagnostic and therapeutic reassurance of well-being.THE MARKETThe company is targeting the US as it's primary market. Currently in the US there are 7 million people diagnosed with AFib and projections for 2015 are 11.5 Million. The predicted incidence is that 1 in every 4 adults over the age of 40 will develop AFib in their lifetime. AFib incidence rises with age, 8 out of 10 people with AFib are over the age of 65. The majority (88%) of AFib patients are symptomatic and may greatly benefit from CardiaCare technology. GO TO MARKETCardiaCare is a physicianprescribed device. Reimbursementwill follow existing codes of remote patient monitoring, noninvasiveprolonged electrical stimulation, parasympathetic nervous system monitoring and external mobile cardiovascular telemetry telehealth. The company has engaged key medical device strategics for clinical and potential commercial collaborationsand KOL physicianshave joinedour team. REVENUE MODELTwo revenue streams including device salesand monthlypremium app & cloud service.NOTESwww.my-cardiacare.com | Israel: +972 (52) 4419884| amos@my-cardiacare.com
  6. Go To Market A specialized multi-sided platform enabled by a mobile app for the patient, a web-app for the doctor, and a proprietary medical device. Patients come on board the Grin platform for treatment fully directed by their assigned local doctor.Grin reduces the complexity and cost of orthodontic treatment ensuring every patient has a chance to be treated by a real local orthodontist. Our patent-pending Remote Monitoring technology allows Doctors to virtually reach inside their patients mouths to ensure continued responsible oversight and care. Overview A high-demand product solution (backed by research of 300+ participants) with buy-inby industry associations, specialists and afliates, the winnerof the Orthodontics Digital Summit Innovation award, Grin’s strategy includes development of proprietary IP at the intersection of digital and medical, unlocking numerous new data-opportunities, and creating the no.1 end-to-end brand for true tele-dental and orthodontics therapy. Management Team Amongst our team we have successfully launched over 10 products within tech unicorns and Fortune 100 companies, combined with decades of clinical know-how and innovation. Dr. Adam Schulhof, CEO & Founder adam@get-grin.comA Columbia DMD and inventor of the award- winningIncognito-Lite appliancesystem. Pamela Oren-Artzi, COO & Founder pamela@get-grin.comPrevious leader ofcutting edge product-lines at Apple, C3.ai and SailPoint Technologies.Alon Lipnik, CPO & Founder alon@get-grin.comExtensive experience managingdevelopment teams at Cisco and the IDF IntelligentCorps. InvestorsPre-Seed from Industry Affiliates, Angels, and F&F.www.get-grin.comEXECUTIVE SUMMARYBusiness Summary Grin is a technology enabled multi-sided platform delivering afordable yet quality care. Our cutting edge remote monitoring device cuts the number of appointments by 60% giving patients convenience and reducing the cost of treatment. Market The global Orthodontic market is currently estimated at 38.4 Billion annually with a 13% CAGR.  Aesthetic options ofered by orthodontics, along with the rising focus on the overall appearance of a person, is fueling its demand across the world. With the advent of advanced technology, the introduction of 3D printers, clear aligners, and other developments are impelling growth in the market.Opportunity Demand for Grin leads to a conservative 5 year projection of 7% market share, with an annual case start of 275K, and an annual revenue point of $880M. COVID-19 Orthodontic patients in ACTIVE appliances are unable to be seen by their Doctors during the quarantine. This will lend towards irreparable damage to their teeth and gums as unchecked forces are acting on their teeth. These occurrences are happening without the patient even being aware. The team realized the severe need to prioritize and expedite Grin’s remote monitoring solution ASAP to give doctors the ability to reach into patients mouths through their smartphones (as a standalone medical device tele-health system).12m Annual Orthodontic case-starts globally13% CAGRprojection for 5 years4m Annual Orthodontic case-starts US13.5k Activeorthodontists in theUSProblem Aside from these developments,however, the delivery of orthodontics within traditional practices has remained costly and inconvenient for today's consumers. This has led to the rise of “do it yourself” companies providing aligners without clinical touch points and direct supervision needed for a majority of cases. SolutionGrin flls this unmet need, with an innovative platform conveniently matching patients with local orthodontists and cutting edge patent pending technology, which reduces visits by over 60%. This reduction in visits, while afording patients amazing convenience, also reduces orthodontists overhead allowing tremendous cost savings for patients. The standalone remote monitoring tele-health system would be available for doctors during 2020 for new and existing patients. Revenue Model •Patient pays for full treatment based on tier model, plus additional LTV. •For B2B Remote Monitoring option, practices pay monthly licensing per patient.
  7. Serenno Medicaldeveloping a novel method to monitor fluid balance and predict, identify and avoid common, life threatening complications duringIntensive Care hospitalizations such as Acute Kidney Injury.COMPANY OVERVIEWA fast growing medical device company that have brought a new and clinically validated methodology to kidney function monitoring within 2 years of development. Device and method protected by2US patents.More uses for the underlying technology in early stages of development.MANAGEMENT TEAMSerenno managing team combines business strategic experience with deep R&D and healthcareexperience.Tomer LarkFounder and CEOtomer@serenno-med.comNoam Hadas Founder and CTO Dr. Shimon EckhouseChairmanProf. Daniel Sessler MD,Department of Outcomes Research, Anesthesiology Institute, Cleveland ClinicMedical AdviserProf. Manu Malbrain MD, ICU directorMedical AdviserINVESTORSAlon MedTechhttps://alon-medtech.com/CONTACTwww.serenno-med.comIsrael: +972 (54) 4915027tomer@serenno-med.comBUSINESS SUMMARYThe SentinelTM system is a pioneering bedside Urine Output (UO)Monitor for hospitalized patients improving Acute Kidney Injury (AKI)prediction and fluid management.Offering a breakthrough solution for robust, accurate and automatic UOmeasurement and AKI assessment-with lower cost, less workload anduse of standard hospital catheter and bag while improving patient safety.OPPORTUNITYAcute Kidney Injury (AKI) -an avoidable, dangerous and common complicationaffects 19 million patients worldwide every year. It occurs in over 55% of all ICUpatients, and 10% of all hospital admissions.AKI triples mortality rates (X3), quadruple risk of readmission (X4) and increases lengthof stay by 50% (X1.5). AKI is hard to treat and reverse once it manifests fullyand so early detection is key to reduce risk, and costs.Each AKI case costs an average of $7K to treat, hospitals are not reimbursed for theseHAC costs.COSTS OF AVOIDABLE AKI ESTIMATED AT $39B WORLDWIDE PER YEARTo detect, assess and possibly prevent AKI onset, ICU patients require accurate andfrequent assessment of Urine Output, an important vital sign, Urine Output (UO) is alsocritical in assessing hemodynamic status and fluid balance. However it is the last metricstill measured manually, inaccurately and intermittently, in the ICU.SOLUTIONThe Sentinel automated system has high ROI for hospitals, with significantly lowerper-patient costs. System performance remain consistent for every patient and hospitalsetting, while maintaining high accuracy in the challenging environment.THE MARKETToday, the most common way to measure UO (andassess AKI risk)are manual graduated urine collection bags (likely over 90% or more of the market), their direct cost is ~10$, they require a nurse to visually check the device once per hour per patient, 24/7. Digital UO measuring devices that have been available in the market of 4-10 years, they all have single patients disposables that are about 3X more expensive and are even less reliable comparing to the manual option, therefore not widely used (some discontinued due to accuracy issues), estimated 5% of the market.2 devices that are very new to the market, estimated under 1% of the market(Q1 2002), are more accurate. Their one major downside is price -100$ to 150$ per patient. That's because they require a disposable that has multiple electronic parts, and make use of custom catheters or bags.Total ICU market estimated $1.5B with 6-8% yearly growth.The Serenno system provides a 35X ROI.REVENUE MODELThe business model is based on disposable repeated sales, and as in every razor/blade model the disposable is the main source of revenue. The controllers are sold at a small profit margin or leased for a reduced price in cases of large standing orders.Disposable sales in the US ICU alone can be up to 6M units per year.
  8. COMPANY OVERVIEWExpain Health is an Oncology-focuseddigital therapeutics company.MANAGEMENT TEAMOur team has a proven track record withlarge-scaleML/AI, patient monitoring solutions, andclinical oncology.Lavi KwiatkowskyCo-founder and CEOTechnology leader, formerly a commander at an elite IDF Intelligence unitDr. Michael Kolodziej, MDFormerly: Flatiron Health, National Director of Oncology at Aetna, US Oncology LeadershipProf. Nathan Cherny, MD, PhDESMO Award recipient, Oncology thought leaderSusan Alpert, MD, PhDChief Regulation at Medtronic, former director of CDRH at the FDAElise Singer, MD, MBACo-founder at Doximity, Chief Medical Officer at CareLinxTaylor SmallFormerly: VP Partnerships, GlookoINVESTORSUpWest VC, a fund based in Palo Alto Morry Blumenfeld, former GM at GE HealthGideon Stein, Chief Scientist, MobileyeGuy Livneh, Cancer survivor& Entrepreneur Ori Eisen, CEO at Trusona, former: VP Bank of America, AmexBUSINESS SUMMARYExpain leverages data to reinvent how oncology treatments are selected, managed, and approved. Expain’s Intelligent Treatment Platform is a digital therapeutic thatprovides personalized symptom monitoring and patient-support. Clinicians leverage Expain’s AI-poweredplatform to monitor and engage patients, streamline communication between visits, and capturesignificantreimbursements for proactive carewhich were previously inaccessible to them.Headquartered in Palo Alto, CA, Expainenables providers to successfully transition to value-based care models and is deployed in leading US oncology practices.OPPORTUNITY$174B1is spent annually in the U.S. on cancer care with $43B on potentially avoidable ER visits and hospitalizations2due to treatment-related symptoms (e.g., nausea/vomiting). Unfortunately, these symptoms go undetected by clinicians 50% of the time3and up to 70% of ER visits during treatment are avoidable4. These undermanaged symptoms represent wasteful spending, unnecessary suffering, and most importantly, detrimental breaks in cancer treatment.Multiple studies (e.g., Basch et al) demonstrate how digital symptom monitoring and support can increase overall survival (5.2 months), improve quality of life (31% of patients), increase time-on-treatment (30%), and reduce ER visits and hospitalizations (17%, 8%)5, 6. This impact is greater than many of today’s targeted cancer therapeutics.Unfortunately, practices lack the toolsto monitor the population at scale, support at-risk patients, and most importantly,capture reimbursements for proactive care.THE MARKETThe oncology market is rapidly transitioning to value-based care models to address the significantandavoidable costsassociated with cancer care. CMS mandates that by 2021, Oncology practices participating in the Oncology Care Model adopt electronic patient-reported outcomes (ePROs) to monitor patients between visits.SOLUTIONExpain’s Intelligent Treatment platform provides personalized symptom monitoring and patient-support. Clinicians leverage Expain’s autonomous triage engine and clinical pathways to detect and support at-risk patients, driving rapid resolution of issues, improved outcomes, and reduced ER visit rates. Expain’s proprietary reimbursement module streamlines complex documentation and billing workflows to enable a significant upside for proactive care. By unlocking the reimbursement opportunity, Expain offers a unique and disruptive model to support practice transformation to value-based Oncology Care Models (OCF/RO).GO TO MARKETExpain has partnered with two leading community-oncology practicessince January and arerapidly accelerating towards 40 cancer centers by the end of 2021.REVENUE MODELExpainestablishes value-based partnerships with Cancer centers. Our platform enables the capture of significant CPT-based revenue while increasing revenue from alternative payment models(APMs). By sharing in this new revenue stream and removing the friction involved with typical subscription models, we see shorter sales cycles (as short as one month) and larger deals (avg: $120K subscription + ~$1M in yearly revenue share)The cost of cancer in the US148% of cancer spend is acute care2Agreement between patient-reported symptoms and their documentation in the medical record370% of ER Visits during cancer treatment are potentially avoidable, Fred Hutch4Overall Survival Results... Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment5, 6NOTESwww.getexpain.com| lavi@getexpain.com
  9. Gynisus is a team of scientists, doctors and engineers that use artificial intelligence to improve the way people are diagnosed and treated. Our SPAI™ platform provides intelligent insights and predictions for the healthcare space.COMPANY OVERVIEWAn award-winning platformandan expert multidisciplinary team:•8200EISP Accelratornamed Gynisus Named Among The Most Innovative And Promising Companies•Poalim Hi-Tech Named Gynisus one ofThe Most RevolutionizedcompaniesSPAI™platform hasnow deployed in a US medical center, phramcuticalsand incorporates data from medical centers worldwide.MANAGEMENT TEAMTeam of tech veterans combines business strategic experience with deep expertise in healthcare.Hila Friedmann, Founder & CEODr. Zoya Gordon, FounderNitin Gupta, Senior Data ScienceJosh Shoemaker, Marketing & SalesAllison Kumar, Regulatory affairsMedicalAdvisorsDr. Eran BronsteinDr. Robert KoppelDr. Shoshana HabermanINVESTORSKent WakefordExpertDOJOJeffrey D’AlessioBUSINESS SUMMARYGynisus is a digital health companythat usesartificial intelligence to improve the way people are diagnosed and treated. Our SPAI™ platform provides intelligent insights and predictions for the healthcare space, from Women’sHealth, through Cardiovascularand Neurologydiseasesand Infectious diseases.Gynisus is one of the few companies that can incorporate EMR data for artificial intelligence-based decisions. Value proposition•For Hospitals-reduce the risk of misdiagnosis, complications, hospitalization days.•For Payers-reduce the number of unnecessary medical tests, frauds, and bureaucracy expenses (such as Prior Authorization). Increase the revenues based on precise medical underwriting, personalized insurance packages.•For Pharmaceuticals-reduce the expenditures for clinical trials and the time to reach the market by identifying patients at high risk and shortening the clinical trial period. •Also, we help pharmaceuticals in the research projects by discovering new biomarkers and matching the patient's profile to a specific medication -precise medicine.•For Retail Clinics–increase the number of clients and offerings per client.OPPORTUNITYDiagnostic errors and other inefficiencies cost the U.S. economy $750 billion each year (including hospitalization days due to the complications caused by misdiagnosis). Also, payers’ loss estimated at $200B for Unnecessary medical tests and $60B of Fraud (related to medical decisions) annually.SOLUTIONWith the outbreak of the COVID-19, Gynisusmanaged to turn around itsSPAI™platform to developthe Infectious Disease Intelligence Platform supports hospitals, nursing homescenters to help slow the spread of COVID-19 by identifying people, prior to testing, who are likely to be infected with the virus, as well as the people who may be infected that have come in contact with them. SPAI™ provides insights in real-time, leveraging AI and its extensive data base of 150,000 patients, including 5,000 with COVID-19.•Provides a prediction of COVID-19 and the complications caused by the virus, based on existing electronic medical records (AUC=0.91).••Provides insights into the patient's probability of deterioration, thereby flagging patients who are at higher risk.••Helps slow the spread of COVID-19 in Hospitals by precisely mapping direct and indirect exposures of medical staff and patients ••Provides a heat map of infections helping to slow the exposure and mitigate the risk inside hospitals and within citiesReal-life data results show:•SPAI™algorithmscorrected over 10%test results of patientsthat found negative (using PCR test) –These findings reduced the number of people that were infectedandmisdiagnosed•SPAI™helps to collect Antibodies ofthe infected and exposed patients and medical staffand savescosts and time.THE MARKETPrimary focus –Hospitals, payers,and pharmacompanies. Additional applicationsfor providers and retail clinics.GO TO MARKETGynisusprovides services as aData Analytics tool and DecisionSupport system for various uses(or an extensionof existing ones), based on thespecificstakeholder. REVENUE MODELAnnual subscription model, per moduleper market,plus implementationfees.NOTESContact: Hila Friedmann, CEOE-mail:Hila@Gynisus.comUS number: 1-424-521-0100ISR number:+972-524409149www.GYNISUS.com
  10. OPPORTUNITY (THE PAIN)Developing a new drug takes 10-15 years and costs $2.6B. Clinical trials drive ~$700M of this cost. In 2019, there were 93,000 active trials with 30,000 new ones. Clinical trials require discipline and consistency from participants over a long period of time (18 months). Although carefully planned, 80% of studies fail to finish as planned with long delays. These delays result with loss of revenue of up to $8M aday. Our research shows, there are many reasons to this from slow recruitment, high dropout, lowadherence, but mainly single root cause Lack of Flexibility! Adapting to the environment the study is part ofas in the COVID-19 period were due to this more than 400 trials were stopped due to lacking the ability to.BUSINESS SUMMARYHabitu disrupts clinical studies with AI based Self Adaptive Trial Journey. We personalize the patient journey by collecting continuous communication with the medical staff, analyzing it in real-time and adapting the trial by automatic interventions.We target Pharma and CROs.CURRENT STATUS•MVP Ready•2 pilots (IL Hospital and US Pharmacy chain-CPESN)•LOI with ReX2 (paid customer)•Academic paper by Harvard Medical School (Sep.’20) •Sales Pipeline-$50K Contract in process with RxE2 LLC-Jun 2020•2 Top 10 Global CROs in discussions•IP -US Provisional Patent•Funding -~$500K private investors & accelerator •Awards -1st Prize Global Award Winner -LEO Pharma•Advisory -2 industry Key Opinion LeadersSOLUTION -SELF ADAPTIVE CLINICAL TRIALS JOURNEYHabitu is the first self-adaptive journey platform for driving patient and sites personalized experience in clinical trials. We create deep behavior knowledge to provide personalized support and encouragement to patients, valuable insights to medical staffand pharma, enabling real time behavior adaptations and automatic interventions to affect predicted patient behaviors for faster, better trial performance.Flexibility and adaptability are the KEY to complete the trial with high quality and on time.VALUE PROPOSITIONMANAGEMENT TEAMTeam of tech executives combines business execution experience with deep expertise in clinical trials and healthcare.Yaniv ZilbermanCo-Founder & CEOyanivz@habitu.healthYoav Grinstein Co-Founder & CPOChain SignalChief Data ScientistEvgeniy BerkovichChief Technology OfficerYair AlmagorChief Business OfficerINVESTORSt-syte, Health-Tech acceleratorhttps://t-syte.com/Gerald Finken, Industry veteranhttps://www.linkedin.com/in/gfinken/www.habitu.Health+972(54)2277517|contact@habitu.healthReduced anxietyMedical supportEmotional attentionPersonalized experienceReduced workloadTasks optimizationIntervention automationReduced time to revenueLower costsReal world insightsTHE MARKET / REVENUE PROJECTIONSTechnology Adoption in Clinical Trials (Pre COVID-19): eClinical Solutions $15.7B by 2027, 13.8% CAGROur market share in 2027 is projected to be 4% which is $600MGO TO MARKETChannels: CRO’s (Parexel, Medpace) andTech solutions (Omnicomm, MMG)Direct Pharma (LEO, Pfizer, MSD, J&J)REVENUE MODELB2B SaaS model,annual subscription tiered per clinical trial size(small, standard, large and corporate licensing)FUTURE DIRECTIONS•Own patient journey, drive patient experience in clinical trial from prospect to post-trial•Clinical trial model restructure, based on insights gleaned from our solution•Participant Compliance -in healthcare treatments based on predicted behavior
We use cookies to provide, improve, protect and promote our services. Visit our Privacy Policy and Privacy Policy FAQs to learn more. You can manage your personal preferences, including your ‘Do not sell or share my personal data to third parties’ setting using the “Customize cookies” button below.